Schering-Plough/Organon merger passes antitrust scrutiny and is completed
The Federal Trade Commission has cleared Schering-Plough's acquisition of Organon BioSciences N.V. from Akzo Nobel N.V. with no requirement for any divestitures in human health products. So Schering-Plough announced the merger is now complete. According to Schering-Plough's CEO Fred Hassan, Organon brings to the table two important pharmaceutical franchises, women's health and central nervous system products. In addition, it has several promising phase III compounds in development.
Click here to see more articles from Drug Topics Daily News.
To go to the Drug Topics homepage, click here.